RecruitingPhase 2NCT01042379
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
Studying Angiosarcoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- QuantumLeap Healthcare Collaborative
- Principal Investigator
- Laura Esserman, MD, MBA, MDUniversity of California, San Francisco
- Intervention
- Standard Therapy(drug)
- Enrollment
- 5000 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2010 – 2031
Study locations (30)
- University of Alabama at Birmingham, Birmingham, Alabama, United States
- Mayo Clinic - Scottsdale, Scottsdale, Arizona, United States
- University of Arizona, Tucson, Arizona, United States
- University of California - Davis, Comprehensive Cancer Center, Davis, California, United States
- City of Hope, Duarte, California, United States
- University of California San Diego, La Jolla, California, United States
- University of Southern California, Los Angeles, California, United States
- HOAG Memorial Hospital Presbyterian, Newport Beach, California, United States
- University of California San Francisco (UCSF), San Francisco, California, United States
- University of Colorado Cancer Center, Aurora, Colorado, United States
- Yale Cancer Center, New Haven, Connecticut, United States
- Georgetown University Medical Center, Washington D.C., District of Columbia, United States
- H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
- Moffitt Cancer Center, Tampa, Florida, United States
- Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01042379 on ClinicalTrials.govOther trials for Angiosarcoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT06898970Intratumoral Vusolimogene Oderparepvec (VO) in Combination With Pembrolizumab for AngiosarcomaVarun Monga, MBBS
- RECRUITINGPHASE2NCT07007273Pembrolizumab for Advanced Cutaneous Sarcomas Not Including AngiosarcomaH. Lee Moffitt Cancer Center and Research Institute
- RECRUITINGNCT06715579Cardiac Angiosarcoma International RegistryImmune Oncology Research Institute
- RECRUITINGPHASE2NCT06849986IO Combined With AI as First-line Treatment for Patients With Soft Tissue Sarcoma(TAIS)Fudan University
- RECRUITINGPHASE2NCT06673628Pembrolizumab Plus Lenvatinib in Unresectable Cutaneous Angiosarcoma PatientsNational Cancer Center, Japan
- RECRUITINGPHASE1NCT06440005A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid TumorsAngiex, Inc.
- RECRUITINGNCT06375941Prospective Observational Study of Localized Angiosarcoma of Any Site: ProStarsItalian Sarcoma Group
- RECRUITINGNCT06541652A French Multicenter Observational Retrospective Study of Rare Primary Liver CancersFederation Francophone de Cancerologie Digestive